ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is Magnesium the Missing Link in Your Heart Healthy Routine?

More evidence for calorie restriction’s longevity effect

A Little Zinc Goes a Long Way

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

Vitamin D deficiency increases risk of chronic headache

VIDEO: The Best Brain Foods That Help Increase Your Memory!

Get the Most From Your Green Tea

Iron (And More) For Lasting, Natural Energy

Metabolic syndrome increases the need for vitamin E

Supplement combo improves bone density, mood, in postmenopausal women

 
Print Page
Email Article

Drug safely retards MS progression for many in two-year, 24-country Phase III trial

  [ 2 votes ]   [ 1 Comment ]
www.ProHealth.com • April 28, 2011


“These exciting results confirm that laquinimod has a significant impact on progression of disability and disease activity, while maintaining a high safety profile.”

The orally-administered drug laquinimod reduced the number of relapses for people with multiple sclerosis (MS), in a large, long-term Phase III clinical study presented as breaking news at the annual meeting of the American Academy of Neurology in April.

The study involved 1,106 people with relapsing-remitting MS* in 24 countries. The participants received either a once-daily oral dose of 0.6 mg laquinimod or a matching placebo for two years. Eighty percent of those taking laquinimod and 77% of those taking the placebo finished the two-year study.

• Patients treated with laquinimod experienced a statistically significant [average] reduction of 23% in annual relapse rate, compared to patients treated with a placebo.

• Additionally, there was a [average] reduction of 36% in disability progression, as well as a 33% reduction in brain atrophy for those people treated with laquinimod.

“These exciting results confirm that laquinimod has a significant impact on progression of disability and disease activity, while maintaining a high safety profile,” said lead author Giancarlo Comi, MD, director of the Department of Neurology and Institute of Experimental Neurology at the Scientific Institute and University Vita-Salute San Raffaele in Milan, Italy.

“This may be attributed to the novel mechanism of action of laquinimod, which effectively and safely addressed both the acute inflammatory activity and the accumulation of irreversible tissue damage,” Dr. Comi adds. “This suggests a substantial future role for laquinimod in the treatment of MS.”

Laquinimod was safe and well tolerated. Overall frequencies of adverse events were low and comparable to those observed in the placebo group.

“The incidence of liver enzyme elevation was higher in laquinimod treated patients,” said Comi. “However, these elevations were temporary, reversible and did not lead to any signs of liver problems.”

[Note: Laquinimod's mechanism of action in treatment of MS is not fully understood, but studies suggest it modulates immune system response from pro-inflammatory to anti-inflammatory by preventing the immune T cells which cause nerve damage in MS from crossing the blood brain barrier & entering the central nervous system. For more, see www.emsp.org.]

* See video briefly describing this and other forms of MS at the American Academy of Neurology website.

Source: American Academy of Neurology, Apr 11, 2011




Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments Post a Comment

Drug for MS
Posted by: victoria
Apr 29, 2011
It's too bad they won't fund studies of Low Dose Naltrexone / LDN
Reply Reply
 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

SAD? Coping with Seasonal Affective Disorder SAD? Coping with Seasonal Affective Disorder
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Strengthen Cell Function with Energy-Boosting Niagen Strengthen Cell Function with Energy-Boosting Niagen
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map